ACE Report Cover
Periarticular and intravenous TXA comparable in blood loss and transfusion rates after TKA
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
Translate this  ACE Report Translate this  ACE Report Translate this  ACE Report
Idioma
Download Download Download
Descargar
Cite this Report Cite this Report Cite this Report
Citar
Add to Favorites Add to Favorites Add to Favorites Remove from Favorites Remove from Favorites Remove from Favorites
+ Favoritos
ARTHROPLASTY
Periarticular and intravenous TXA comparable in blood loss and transfusion rates after TKA .

OrthoEvidence Journal (OE Journal) - ACE Report

OE Journal. 2016;4(20):5 BMC Musculoskelet Disord. 2016 Jul 26;17:313.
Autores colaboradores

P Pinsornsak S Rojanavijitkul S Chumchuen

60 patients scheduled for unilateral total knee arthroplasty were randomized to be administered either periarticular or intravenous tranexamic acid (TXA). The purpose of this study was to compare blood loss and adverse events throughout the first 48-hours post-surgery. The results from this trial demonstrated non-significant differences between groups for postoperative blood loss volume, hematocrit levels, hemoglobin concentration, the number of patients requiring transfusion, VAS pain scores, and thigh/leg circumference when evaluated at 24- or 48-hours postoperatively.


Detalles de la financiación de la publicación +
Financiación:
Non-funded
Conflictos:
None disclosed

Riesgo de sesgo

6/10

Criterios de información

15/20

Índice de fragilidad

N/A

Was the allocation sequence adequately generated?

Was allocation adequately concealed?

Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?

Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?

Blinding Patients: Was knowledge of the allocated interventions adequately prevented?

Was loss to follow-up (missing outcome data) infrequent?

Are reports of the study free of suggestion of selective outcome reporting?

Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?

Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?

Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?

Sí = 1

Incierto = 0,5

No relevante = 0

No = 0

La evaluación de los criterios de información evalúa la transparencia con la que los autores informan de las características metodológicas y del ensayo dentro de la publicación. La evaluación se divide en cinco categorías que se presentan a continuación.

1/4

Randomization

2/4

Outcome Measurements

4/4

Inclusion / Exclusion

4/4

Therapy Description

4/4

Statistics

Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65

El Índice de Fragilidad es una herramienta que ayuda en la interpretación de hallazgos significativos, proporcionando una medida de fuerza para un resultado. El Índice de Fragilidad representa el número de eventos consecutivos que es necesario añadir a un resultado dicotómico para que el hallazgo deje de ser significativo. Un número pequeño representa un hallazgo más débil y un número grande un hallazgo más fuerte.

¿Por qué se necesitaba ahora este estudio?

Intravenous tranexamic acid remains a popular mode of reducing postoperative blood loss after total knee arthroplasty. Despite its well-established anti-fibrinolytic efficacy, potential drawbacks such as thrombus formation and venous thromboembolism (VTE) still remain major concerns with the intravenous administration method. As a result, it has been suggested that other methods of application, such as topical administration or periarticular injection, may offer similar outcomes while reducing the risk of developing these complications.

¿Cuál era la pregunta principal de la investigación?

In patients undergoing unilateral total knee arthroplasty, did the periarticular injection of tranexamic acid (TXA) produce comparable results to conventional intravenous TXA in terms of postoperative blood loss, hemoglobin concentration, and the need for blood transfusion during the first 48 hours post-surgery?

Características del estudio +
Población:
60 patients (50-80 years) with knee osteoarthritis scheduled for total knee arthroplasty were included. Patients who reported daily aspirin use were asked to stop medication at least seven days prior to scheduled surgery. All patients received cemented, posterior-stabilized, fixed bearing prostheses without patella resurfacing. All procedures were performed via a medial parapatellar approach under tourniquet control.
Intervención:
Periarticular group: patients received 750 mg periarticular tranexamic acid injection (15 cc of 250 mg/5mL Transamin, OLIC Thailand Ltd) to soft tissues surrounding the medial capsule, lateral capsule, and quadriceps muscle (n=30; 67.63+/-7.96, 25F/5M).
Comparación:
Intravenous group: patients received 750 mg intravenous tranexamic acid injection (15 cc of 250 mg/5mL solution) (n=30; 69.97+/-7.55, 23F/7M).
Resultados:
The primary outcomes included drain volume of postoperative blood loss, changes in serum hemoglobin, and requirement of blood transfusion. The requirement of blood transfusion was defined as a hemoglobin concentration less than 10 g/dL, or if patients demonstrated clinical symptoms of anemia (chest pain, heart failure, idiopathic tachycardia or hypotension). Secondary outcomes included knee diameter (swelling), local soft tissue complications, skin necrosis, venous thromboembolism (VTE), and VAS pain.
Métodos:
RCT: prospective, un-blinded, pilot study
Tiempo:
Outcomes were assessed at 24 and 48 hours postoperatively.
¿Cuáles fueron los hallazgos importantes?
  • The volume of blood present in Hemovac drain (postoperative blood loss) was not significantly different between periarticular and intravenous groups when compared at the 24-hour follow-up (300+/-128 vs. 334+/-124mL, respectively; p=0.279) or 24-48 hour follow-up (145+/-92 vs. 186+/-106mL, respectively; p=0.094).
  • Hematocrit levels for periarticular and intravenous groups were not significantly different when compared at 24 hours (29.7 vs 30.4; p=0.550) and 48 hours (31.0 vs. 31.8; p=0.352) postoperatively.
  • Hemoglobin concentrations were not significantly different between periarticular and intravenous groups when compared at 24 hours (9.60 vs 10.09; p=0.215) and 48 hours (10.16 vs 10.40; p=0.693) postoperatively.
  • The number of patients requiring blood transfusion was not significantly different between periarticular and intravenous groups (9 vs. 7, p=0.928).
  • Differences between periarticular and intravenous groups for thigh and leg circumference were not significant at 48 hours (p=0.398 and 0.052 respectively).
  • VAS pain scores measured at 24 hours (p=0.889) and 48 hours (p=0.724), Knee flexion at time of hospital discharge(p=0.087), and total length of hospital stay ( p=0.276) were comparable between periarticular and intravenous groups.
¿Qué es lo que más debo recordar?

For patients undergoing total knee arthroplasty, periarticular and intravenous administration of tranexamic acid (TXA) resulted in comparable postoperative blood loss volume, hematocrit levels, hemoglobin concentration, the number of patients requiring transfusion, VAS pain scores, and thigh/leg circumference throughout a 48-hour postoperative period.

¿Cómo afectará esto al cuidado de mis pacientes?

The results of this study demonstrated comparable effects of either periarticular or intravenous tranexamic acid on postoperative blood loss and clinical outcomes for patients undergoing unilateral TKA. Further investigation with dose-response analyses, a control group, and larger patient populations is recommended to both determine optimal dosing of either periarticular or intravenous TXA dosing and to determine if differences in safety outcomes exist.

DESCARGO DE RESPONSABILIDAD

El contenido de esta página tiene únicamente fines informativos y no pretende sustituir el consejo, diagnóstico o tratamiento médico profesional. Si necesita tratamiento médico, busque siempre el consejo de su médico o acuda al servicio de urgencias más cercano. Las opiniones, creencias y puntos de vista expresados por las personas sobre el contenido que se encuentra en esta página no reflejan las opiniones, creencias y puntos de vista de OrthoEvidence.

0 de 4 artículos mensuales GRATIS desbloqueados
Ha alcanzado su límite de vistas de 4 artículos gratuitos este mes

Acceda a OrtoEvidencia por tan sólo 1,99 $ a la semana.

Manténgase conectado con las últimas pruebas. Cancele en cualquier momento.
  • Valoraciones críticas de los últimos ensayos controlados aleatorizados de gran impacto y revisiones sistemáticas en ortopedia
  • Acceso al contenido del podcast OrthoEvidence, que incluye colaboraciones con el Journal of Bone and Joint Surgery, entrevistas con cirujanos reconocidos internacionalmente y mesas redondas sobre noticias y temas ortopédicos
  • Suscripción a The Pulse, un boletín quincenal basado en la evidencia y diseñado para ayudarle a tomar mejores decisiones clínicas
Upgrade
Close Dialog
Bienvenido
¿Ha olvidado su contraseña?
Comience hoy mismo su prueba GRATUITA

Su cuenta estará afiliada a
e incluye acceso gratuito a OrthoEvidence


O
¿Olvidó su contraseña?

O
Compruebe su correo electrónico

Si existe una cuenta con la dirección de correo electrónico proporcionada, se le enviará un correo electrónico para restablecer la contraseña. Si no ve el correo electrónico, compruebe su carpeta de correo no deseado o spam.

Si necesita más ayuda póngase en contacto con nuestro equipo de asistencia.

Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Traducir Informe ACE

OrthoEvidence utiliza un servicio de traducción de terceros para que el contenido sea accesible en varios idiomas. Tenga en cuenta que, aunque se hace todo lo posible para garantizar la exactitud, las traducciones no siempre son perfectas.

Cómo citar esto ACE Report

OrthoEvidence. Periarticular and intravenous TXA comparable in blood loss and transfusion rates after TKA. OE Journal. 2016;4(20):5. Available from: https://myorthoevidence.com/AceReport/Show/periarticular-and-intravenous-txa-comparable-in-blood-loss-and-transfusion-rates-after-tka

Copiar cita
Inicie sesión para activar esta función

Para acceder a esta función, debe iniciar sesión en una cuenta activa de OrthoEvidence. Por favor, inicie sesión o cree una cuenta de prueba GRATUITA.

Función de miembro Premium

Para acceder a esta función, debe iniciar sesión en una cuenta Premium de OrthoEvidence.

Compartir ACE Report